Complete Filing Data
P3 Health Partners Inc. reported Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents of $25.81 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean P3 Health Partners Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income * | -$147.9M | -$135.8M | -$57.8M | -$270.1M | -$10.1M | -$31.4M | -$42.0M |
| Operating Income Loss | -$270.3M | -$320.7M | -$167.9M | -$1.56B | -$58.9M | -$28.6M | -$39.5M |
| General And Administrative Expense | $106.3M | $112.6M | $122.4M | $157.3M | $17.0M | $53.4M | $36.4M |
| Nonoperating Income Expense | -$50.8M | $14.7M | -$15.8M | $1.2M | $950.0K | -$2.8M | -$2.4M |
| Selling And Marketing Expense | $918.0K | $1.3M | $3.2M | $5.1M | $364.0K | $1.5M | $801.7K |
| Revenue From Contract With Customer Excluding Assessed Tax | $1.46B | $1.50B | $1.27B | $1.05B | $58.8M | $491.1M | $145.5M |
| Operating Expenses | $1.73B | $1.82B | $1.43B | $2.61B | $117.7M | $519.7M | $185.0M |
| Interest Income Expense Net | -$55.0M | -$22.2M | -$16.0M | -$11.4M | -$851.0K | -$2.5M | -$2.5M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$321.1M | -$306.0M | -$183.7M | -$1.56B | -$57.9M | -$31.4M | -$42.0M |
| Net Income Loss Attributable To Noncontrolling Interest | -$175.1M | -$174.5M | -$128.7M | -$1.29B | -$47.9M | ||
| Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest | -$147.9M | -$135.8M | -$57.8M | -$270.1M | -$10.1M | ||
| Other Nonoperating Income Expense | -$3.4M | $1.5M | -$249.0K | $2.8M | -$471.0K | -$290.7K | $98.0K |
| Income Tax Expense Benefit | $2.0M | $4.4M | $2.7M | $1.9M | $0.00 | $0.00 | $0.00 |
| Goodwill Impairment Loss | $0.00 | $1.31B | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$31.6M | -$20.4M | -$20.5M | -$46.5M | -$12.0M | -$18.7M | -$13.3M | -$9.8M | -$9.2M | -$11.2M | -$154.4M | -$10.6M | -$32.1M | -$29.5M | -$24.7M | $0.00 | |
| Operating Income Loss | -$44.2M | -$34.1M | -$38.1M | -$107.0M | -$31.3M | -$43.8M | -$33.8M | -$21.0M | -$48.8M | -$60.0M | -$912.2M | -$52.2M | -$28.1M | -$26.0M | -$13.0M | ||
| General And Administrative Expense | $22.1M | $23.3M | $25.0M | $27.2M | $26.6M | $27.4M | $33.1M | $27.2M | $37.6M | $37.9M | $41.1M | $38.6M | $20.4M | $18.4M | $15.1M | ||
| Nonoperating Income Expense | -$25.2M | -$7.6M | -$5.1M | $535.0K | $3.5M | -$3.7M | -$3.1M | -$6.3M | -$3.3M | -$5.3M | $9.1M | -$8.6M | -$3.9M | -$3.5M | -$11.7M | ||
| Selling And Marketing Expense | $251.0K | $151.0K | $181.0K | $134.0K | $414.0K | $322.0K | $654.0K | $857.0K | $1.0M | $1.1M | $1.4M | $865.0K | $491.4K | $356.5K | $270.2K | ||
| Revenue From Contract With Customer Excluding Assessed Tax | $345.3M | $355.8M | $373.2M | $362.1M | $379.2M | $388.5M | $288.4M | $329.1M | $302.1M | $248.3M | $269.5M | $273.5M | $156.2M | $144.6M | $151.3M | ||
| Operating Expenses | $389.5M | $389.9M | $411.3M | $469.1M | $410.5M | $432.3M | $322.2M | $350.1M | $350.9M | $308.3M | $1.18B | $325.7M | $184.3M | $170.6M | $164.3M | ||
| Interest Income Expense Net | -$20.5M | -$10.1M | -$8.7M | -$5.6M | -$5.4M | -$4.3M | -$4.0M | -$3.9M | -$4.1M | -$3.0M | -$2.7M | -$2.8M | -$2.5M | -$2.4M | -$2.1M | ||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$69.5M | -$41.7M | -$43.2M | -$106.5M | -$27.8M | -$47.5M | -$36.9M | -$27.4M | -$52.2M | -$65.3M | -$903.1M | -$60.8M | -$32.1M | -$29.5M | -$24.7M | ||
| Net Income Loss Attributable To Noncontrolling Interest | -$37.9M | -$23.3M | -$23.8M | -$56.3M | -$16.8M | -$30.9M | -$24.0M | -$17.8M | -$43.2M | -$54.2M | -$748.8M | -$50.2M | |||||
| Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest | -$31.6M | -$20.4M | -$20.5M | -$46.5M | -$12.0M | -$18.7M | -$13.3M | -$9.8M | -$9.2M | -$11.2M | -$154.4M | -$10.6M | |||||
| Other Nonoperating Income Expense | -$2.2M | $583.0K | $318.0K | $445.0K | $291.0K | $337.0K | $190.0K | -$741.0K | $96.0K | $213.0K | -$34.0K | -$6.0K | |||||
| Income Tax Expense Benefit | $11.0K | $2.0M | $1.1M | -$3.6M | $968.0K | $2.1M | $412.0K | $226.0K | $290.0K | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Goodwill Impairment Loss | $0.00 | $0.00 | $463.5M | $0.00 | $851.5M | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | -$155.2M | $75.9M | $142.1M | $5.9M | $273.6M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $25.8M | $44.1M | $40.9M | $18.5M | $140.8M | $39.9M | $32.9M | $1.4M |
| Cash And Cash Equivalents At Carrying Value | $25.0M | $38.8M | $36.3M | $17.5M | $140.5M | $36.3M | $32.6M | |
| Retained Earnings Accumulated Deficit | -$651.1M | -$503.2M | -$367.3M | -$309.5M | -$39.4M | -$130.5M | ||
| Liabilities Current | $545.3M | $496.4M | $299.4M | $241.7M | $198.8M | $90.6M | ||
| Liabilities And Stockholders Equity | $656.6M | $783.4M | $861.0M | $876.6M | $2.36B | $106.4M | ||
| Liabilities | $796.9M | $633.9M | $427.3M | $353.9M | $299.9M | $146.0M | ||
| Assets Current | $133.1M | $184.1M | $166.0M | $100.7M | $199.9M | $90.9M | ||
| Assets | $656.6M | $783.4M | $861.0M | $876.6M | $2.36B | $106.4M | ||
| Restricted Cash Current | $795.0K | $5.3M | $4.6M | $920.0K | $356.0K | $3.6M | $312.4K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$18.3M | $3.2M | $22.5M | -$122.4M | $135.5M | $7.0M | $31.5M | |
| Repayments Of Long Term Debt | $1.1M | $31.0M | $0.00 | $3.6M | $8.0K | $1.5M | $14.6M | |
| Operating Lease Liability Noncurrent | $11.5M | $11.3M | $13.6M | $11.5M | $6.3M | $3.6M | ||
| Long Term Debt Noncurrent | $228.4M | $108.9M | $108.3M | $94.4M | $80.0M | $45.4M | ||
| Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest | $5.9M | $273.6M | -$130.2M | -$99.1M | -$55.7M | |||
| Property Plant And Equipment Net | $3.4M | $5.7M | $8.7M | $8.8M | $8.0M | $6.2M | ||
| Prepaid Expense And Other Assets Current | $11.4M | $14.4M | $3.6M | $2.6M | $7.0M | $5.2M | ||
| Interest Payable Current | $429.0K | $2.3M | $23.6M | $14.1M | $8.8M | $4.1M | ||
| Health Plans Settlements Payable Current | $69.8M | $55.6M | $35.0M | $13.6M | $22.5M | $13.7M | ||
| Health Plan Settlement Receivables Current | $92.5M | $121.3M | $118.5M | $72.1M | $50.3M | $45.0M | ||
| Claims Payable Current | $287.8M | $255.1M | $178.0M | $151.2M | $102.0M | $56.9M | ||
| Intangible Assets Net Excluding Goodwill | $492.4M | $574.4M | $666.7M | $751.1M | $835.8M | |||
| Redeemable Noncontrolling Interest Equity Carrying Amount | $15.0M | $73.6M | $291.5M | $516.8M | $1.79B | |||
| Clinic Fees And Insurance Receivables Net Current | $3.4M | $3.9M | $3.0M | $7.5M | $1.1M | $676.0K | ||
| Accrued Liabilities Current | $42.4M | $29.4M | $36.9M | $16.6M | ||||
| Other Assets Noncurrent | $27.8M | $19.2M | $19.5M | $16.0M | $10.6M | |||
| Accounts Payable Current | $11.7M | $8.4M | $8.7M | $11.5M | $5.5M | |||
| Business Combination Contingent Consideration Liability Noncurrent | $0.00 | $4.9M | $4.8M | $3.5M | ||||
| Adjustment To Equity Remeasurement Adjustment | $3.9M | $22.8M | $117.9M | |||||
| Warrant Liabilities Noncurrent | $2.5M | $10.3M | $1.1M | $1.5M | ||||
| Employee Related Liabilities Current | $2.0M | $2.7M | $3.5M | $8.2M | ||||
| Health Plan Settlement Receivables Allowance For Credit Loss Current | $150.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | -$18.7M | $44.5M | $63.3M | $120.5M | $166.8M | $146.6M | $187.9M | -$136.2M | -$2.7M | $78.1M | $108.6M | $263.0M | -$10.2M | -$15.1M | -$4.6M | $22.7K | $0.00 | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $38.5M | $39.3M | $41.3M | $68.1M | $78.2M | $32.3M | $57.4M | $65.5M | $8.4M | $35.4M | $63.9M | $110.7M | $4.7M | $16.5M | $26.0M | |||
| Cash And Cash Equivalents At Carrying Value | $37.7M | $38.6M | $40.1M | $63.0M | $73.1M | $27.3M | $52.6M | $59.9M | $7.2M | $34.4M | $63.1M | $110.3M | $4.3M | $16.3M | $22.3M | |||
| Retained Earnings Accumulated Deficit | -$575.6M | -$544.0M | -$523.7M | -$444.6M | -$398.1M | -$386.0M | -$341.9M | -$328.6M | -$318.8M | -$215.5M | -$204.3M | -$50.0M | -$10.2M | -$5.7M | $4.8M | |||
| Liabilities Current | $424.0M | $505.0M | $507.0M | $405.3M | $352.3M | $333.7M | $267.3M | $250.4M | $269.7M | $227.1M | $228.8M | $234.4M | $390.4K | $186.4K | $175.6K | |||
| Liabilities And Stockholders Equity | $683.6M | $731.6M | $783.9M | $833.3M | $892.8M | $855.9M | $896.9M | $909.0M | $867.4M | $1.38B | $1.44B | $2.36B | $316.6M | $317.1M | $317.7M | |||
| Liabilities | $664.6M | $644.4M | $662.8M | $569.4M | $527.9M | $470.5M | $395.9M | $377.9M | $396.4M | $331.0M | $328.5M | $341.6M | $10.6M | $15.9M | $6.0M | |||
| Assets Current | $135.6M | $156.5M | $191.4M | $215.1M | $242.1M | $183.0M | $179.7M | $172.1M | $109.4M | $124.2M | $171.0M | $213.4M | $353.3K | $818.8K | $1.4M | |||
| Assets | $683.6M | $731.6M | $783.9M | $833.3M | $892.8M | $855.9M | $896.9M | $909.0M | $867.4M | $1.38B | $1.44B | $2.36B | $316.6M | $317.1M | $317.7M | |||
| Restricted Cash Current | $748.0K | $746.0K | $1.2M | $5.1M | $5.1M | $5.0M | $4.9M | $5.6M | $1.2M | $1.0M | $753.9K | $356.2K | $346.3K | $223.9K | $3.7M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$2.8M | -$8.6M | -$10.1M | -$30.1M | -$13.9M | |||||||||||||
| Repayments Of Long Term Debt | $341.0K | $430.0K | $0.00 | $1.2M | ||||||||||||||
| Operating Lease Liability Noncurrent | $12.1M | $10.3M | $11.0M | $11.2M | $12.2M | $12.9M | $13.6M | $11.8M | $12.8M | $11.2M | $10.6M | $6.3M | ||||||
| Long Term Debt Noncurrent | $214.2M | $102.0M | $106.1M | $133.2M | $133.1M | $118.1M | $108.3M | $108.2M | $108.1M | $80.0M | $80.0M | $80.0M | ||||||
| Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest | $78.1M | $108.6M | $263.0M | -$215.0M | -$183.3M | -$154.4M | ||||||||||||
| Property Plant And Equipment Net | $3.9M | $4.7M | $5.3M | $6.3M | $7.5M | $8.1M | $9.4M | $9.5M | $8.9M | $9.5M | $8.3M | $8.3M | ||||||
| Prepaid Expense And Other Assets Current | $11.4M | $16.2M | $15.0M | $11.0M | $8.5M | $6.9M | $2.8M | $2.2M | $2.8M | $3.5M | $5.1M | $6.7M | ||||||
| Interest Payable Current | $271.0K | $26.9M | $12.4M | $35.9M | $31.9M | $28.0M | $21.2M | $18.7M | $16.3M | $12.7M | $11.3M | $10.0M | ||||||
| Health Plans Settlements Payable Current | $53.5M | $41.9M | $56.7M | $41.2M | $22.9M | $22.0M | $35.4M | $6.9M | $12.4M | $20.6M | $18.0M | $18.6M | ||||||
| Health Plan Settlement Receivables Current | $82.0M | $93.5M | $129.4M | $123.3M | $153.3M | $143.7M | $117.2M | $102.5M | $93.2M | $81.5M | $99.8M | $94.6M | ||||||
| Claims Payable Current | $253.7M | $256.0M | $268.7M | $230.7M | $233.8M | $222.2M | $155.5M | $158.5M | $164.9M | $134.7M | $139.3M | $137.4M | ||||||
| Intangible Assets Net Excluding Goodwill | $512.9M | $533.4M | $553.9M | $594.9M | $624.7M | $645.7M | $687.9M | $709.0M | $730.2M | $772.4M | $793.6M | $814.7M | ||||||
| Redeemable Noncontrolling Interest Equity Carrying Amount | $37.6M | $42.7M | $57.8M | $143.4M | $198.0M | $238.8M | $313.1M | $667.2M | $473.7M | $974.1M | $1.01B | $1.75B | ||||||
| Clinic Fees And Insurance Receivables Net Current | $3.7M | $7.6M | $5.4M | $2.5M | $2.2M | $48.0K | $318.0K | $1.0M | $1.9M | $767.4K | ||||||||
| Accrued Liabilities Current | $35.8M | $29.7M | $28.0M | $49.2M | $39.9M | $28.6M | $21.0M | $22.5M | $21.3M | $374.9K | $170.9K | $118.8K | $2.3K | |||||
| Other Assets Noncurrent | $31.1M | $37.0M | $33.2M | $17.1M | $18.4M | $19.1M | $20.0M | $18.3M | $18.9M | |||||||||
| Accounts Payable Current | $9.9M | $14.4M | $11.5M | $13.5M | $8.0M | $11.6M | $11.6M | $9.2M | $15.8M | |||||||||
| Business Combination Contingent Consideration Liability Noncurrent | $0.00 | $4.9M | $4.9M | $4.9M | $4.9M | $4.9M | $4.7M | $3.7M | $3.6M | |||||||||
| Adjustment To Equity Remeasurement Adjustment | -$4.8M | -$8.2M | -$8.0M | -$1.7M | $24.1M | $1.2M | -$358.0K | $119.6M | ||||||||||
| Warrant Liabilities Noncurrent | $7.5M | $5.0M | $7.0M | $19.7M | $25.5M | $869.0K | $1.8M | $2.6M | $868.0K | |||||||||
| Employee Related Liabilities Current | $1.3M | $1.2M | $3.2M | $4.4M | $3.7M | $5.0M | $5.6M | $5.1M | $7.4M | |||||||||
| Health Plan Settlement Receivables Allowance For Credit Loss Current | $150.0K | $150.0K | $150.0K | $150.0K | $150.0K | $150.0K | $150.0K | $150.0K | $150.0K | $150.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Financing Activities | $72.8M | $98.8M | $100.3M | $11.4M | $198.7M | $34.8M | $63.6M |
| Net Cash Provided By Used In Operating Activities | -$91.2M | -$110.1M | -$76.0M | -$126.0M | -$15.3M | -$24.6M | -$28.3M |
| Net Cash Provided By Used In Investing Activities | $129.0K | $14.5M | -$1.8M | -$7.7M | -$47.9M | -$3.2M | -$3.9M |
| Share Based Compensation | $5.6M | $5.8M | $6.0M | $19.4M | $4.6M | $447.5K | $474.0K |
| Increase Decrease In Interest Payable Net | -$1.9M | $0.00 | $9.6M | $5.3M | -$498.0K | $1.8M | $2.2M |
| Payments To Acquire Property Plant And Equipment | $0.00 | $1.8M | $2.2M | $120.0K | $2.9M | $1.5M | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$3.0M | $10.8M | $1.2M | -$4.3M | $4.7M | ||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $11.1M | -$8.1M | $16.0M | $6.1M | $7.7M | ||
| Proceeds From Issuance Of Long Term Debt | $73.0M | $88.1M | $14.1M | $15.0M | $25.0M | $36.4M | $16.2M |
| Increase Decrease In Operating Lease Liability | $641.0K | $53.0K | -$450.0K | $4.0M | -$22.0K | ||
| Increase Decrease In Health Plan Receivables Premiums | -$28.7M | $2.8M | $46.6M | $21.8M | -$3.2M | $27.5M | $9.7M |
| Increase Decrease In Health Plan Payables Premiums | $14.3M | $20.6M | $21.4M | -$8.9M | -$2.6M | $8.8M | $1.9M |
| Increase Decrease In Clinic Fees Insurance And Other Receivables | $2.3M | $990.0K | -$4.6M | $5.3M | -$1.5M | ||
| Increase Decrease In Other Noncurrent Assets | $3.5M | $43.0K | $58.0K | -$100.0K | |||
| Increase Decrease In Claims Payables | $49.2M | -$971.0K | $37.1M | $12.1M | |||
| Increase Decrease In Employee Related Liabilities | -$772.0K | -$784.0K | $282.0K | $1.9M | |||
| Increase Decrease In Claims Payable | $32.7M | $77.1M | $26.8M | $49.2M | |||
| Proceeds From Short Term Debt | $1.1M | $1.9M | $0.00 | $3.4M | |||
| Payments To Acquire Businesses Gross | $0.00 | $5.5M | $47.9M | $130.0K | |||
| Payments Of Debt Issuance Costs | $186.0K | $103.0K | $173.0K | $0.00 | $375.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|
| Net Cash Provided By Used In Financing Activities | $30.7M | $11.4M | $14.1M | -$1.2M | -$22.2K |
| Net Cash Provided By Used In Operating Activities | -$33.5M | -$20.0M | -$23.7M | -$27.8M | -$13.1M |
| Net Cash Provided By Used In Investing Activities | $0.00 | $0.00 | -$464.0K | -$1.1M | -$729.7K |
| Share Based Compensation | $1.8M | $1.4M | $977.0K | $11.7M | $460.5K |
| Increase Decrease In Interest Payable Net | $5.6M | $4.4M | $2.3M | $1.2M | $874.9K |
| Payments To Acquire Property Plant And Equipment | $0.00 | $464.0K | $877.0K | $656.2K | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $558.0K | $3.3M | $454.0K | -$216.0K | $162.2K |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $1.6M | -$5.6M | $8.3M | $4.0M | |
| Proceeds From Issuance Of Long Term Debt | $30.0M | $10.0M | $14.1M | $0.00 | |
| Increase Decrease In Operating Lease Liability | -$104.0K | -$37.0K | -$359.0K | $58.0K | |
| Increase Decrease In Health Plan Receivables Premiums | $8.1M | $25.2M | $21.3M | $44.3M | $8.2M |
| Increase Decrease In Health Plan Payables Premiums | $1.2M | -$12.9M | -$1.2M | -$3.9M | $2.0M |
| Increase Decrease In Clinic Fees Insurance And Other Receivables | $1.5M | -$2.9M | -$2.5M | -$805.0K | |
| Increase Decrease In Other Noncurrent Assets | $14.3M | $17.0K | $1.4M | $0.00 | |
| Increase Decrease In Claims Payables | $35.4M | $3.3M | |||
| Increase Decrease In Employee Related Liabilities | $494.0K | $1.5M | -$823.0K | $1.4M | |
| Increase Decrease In Claims Payable | $13.6M | $44.2M | $13.7M | $35.5M | |
| Proceeds From Short Term Debt | $1.1M | $1.9M | |||
| Payments To Acquire Businesses Gross | |||||
| Payments Of Debt Issuance Costs | $139.0K | $0.00 |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Earnings Per Share Diluted | $-45.26 | $-54.06 | $-0.63 | $-6.50 | $-0.24 |
| Earnings Per Share Basic | $-45.26 | $-46.78 | $-0.61 | $-6.50 | $-0.24 |
| Weighted Average Number Of Shares Outstanding Basic | 3.3M | 2.9M | 94.9M | 41.6M | 41.6K |
| Weighted Average Number Of Diluted Shares Outstanding | 3.3M | 2.9M | 294.6M | 41.6M | 41.6K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share Diluted | $-9.67 | $-6.23 | $-6.28 | $-15.70 | $-7.37 | $-7.86 | $-0.12 | $-0.09 | $-0.22 | $-0.27 | $-3.73 | $-0.25 |
| Earnings Per Share Basic | $-9.67 | $-6.23 | $-6.28 | $-14.36 | $-4.40 | $-7.86 | $-0.12 | $-0.09 | $-0.22 | $-0.27 | $-3.71 | $-0.25 |
| Weighted Average Number Of Shares Outstanding Basic | 3.3M | 3.3M | 3.3M | 3.2M | 2.7M | 2.4M | 114.2M | 107.5M | 41.6M | 41.6M | 41.6M | 41.6M |
| Weighted Average Number Of Diluted Shares Outstanding | 3.3M | 3.3M | 3.3M | 3.3M | 2.8M | 2.4M | 312.7M | 107.5M | 41.6M | 243.0M | 242.1M | 41.6M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Premium Deficiency Testing Expense Long Duration Contract Amount1 | $18.7M | $53.7M | -$12.7M | -$11.5M | $26.3M | -$20.5M | $6.4M |
| Medical Expenses | $1.52B | $1.56B | $1.23B | $1.06B | $66.9M | $484.5M | $141.0M |
| Depreciation And Amortization | $84.2M | $86.1M | $86.7M | $87.3M | $7.1M | $795.2K | $399.2K |
| Fair Value Adjustment Of Warrants | -$7.9M | -$22.1M | -$433.0K | -$9.9M | -$2.3M | ||
| Additional Paid In Capital | $495.9M | $579.1M | $509.4M | $315.4M | $312.9M | ||
| Premium Deficiency Reserve Current | $86.1M | $67.4M | $13.7M | $26.4M | $37.8M | $0.00 | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $5.6M | $5.8M | $5.2M | $1.8M | |||
| Amortization Of Financing Costs And Discounts | $13.6M | $87.0K | $472.0K | $0.00 | $1.8M | ||
| Interest Paid Net | $13.6M | $14.2M | $5.8M | $5.7M | $1.3M | $685.4K | $560.2K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Premium Deficiency Testing Expense Long Duration Contract Amount1 | -$23.7M | -$6.0M | -$7.0M | $18.2M | -$3.4M | $1.0M | -$12.5M | -$2.0M | $5.1M | -$7.3M | -$1.5M | -$1.3M | $1.6M | $1.0M | $2.0M | |
| Medical Expenses | $369.8M | $351.4M | $372.0M | $401.9M | $365.2M | $382.1M | $279.2M | $302.3M | $285.6M | $254.8M | $267.4M | $265.8M | $161.3M | $150.4M | $146.6M | |
| Depreciation And Amortization | $21.0M | $21.1M | $21.1M | $21.7M | $21.7M | $21.5M | $21.7M | $21.8M | $21.5M | $21.8M | $21.7M | $21.8M | $456.4K | $429.8K | ||
| Fair Value Adjustment Of Warrants | $2.5M | -$2.0M | -$3.3M | -$5.7M | -$8.7M | -$216.0K | -$755.0K | $1.7M | -$649.0K | $2.6M | -$11.8M | $5.9M | -$5.5M | $9.9M | -$5.3M | |
| Additional Paid In Capital | $556.9M | $588.5M | $586.9M | $565.1M | $564.9M | $532.6M | $529.8M | $192.4M | $316.1M | $293.6M | $312.9M | $312.9M | $0.00 | $10.7M | $182.4K | $24.2K |
| Premium Deficiency Reserve Current | $30.7M | $54.4M | $60.4M | $29.4M | $11.3M | $14.7M | $17.0M | $29.5M | $31.5M | $27.7M | $35.0M | $36.5M | ||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.0M | $1.6M | $1.4M | $2.1M | $740.0K | $686.0K | $0.00 | $0.00 | ||||||||
| Amortization Of Financing Costs And Discounts | $331.0K | -$140.0K | $279.0K | $0.00 | ||||||||||||
| Interest Paid Net |
Most recent annual filing with the SEC: March 26, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.